Kyowa Kirin Co., Ltd. (TYO:4151)
Japan
· Delayed Price · Currency is JPY 2,201.50
-50.00 (-2.22%)
At close: Mar 9, 2026
Kyowa Kirin Revenue
In the year 2025, Kyowa Kirin had annual revenue of 496.83B JPY with 0.26% growth. Kyowa Kirin had revenue of 147.38B in the quarter ending December 31, 2025, with 11.01% growth.
Revenue
496.83B
Revenue Growth
+0.26%
P/S Ratio
2.32
Revenue / Employee
87.64M
Employees
5,669
Market Cap
1,152.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 496.83B | 1.27B | 0.26% |
| Dec 31, 2024 | 495.56B | 53.33B | 12.06% |
| Dec 31, 2023 | 442.23B | 43.86B | 11.01% |
| Dec 31, 2022 | 398.37B | 46.13B | 13.09% |
| Dec 31, 2021 | 352.25B | 33.89B | 10.65% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ono Pharmaceutical | 509.35B |
| Santen Pharmaceutical | 287.99B |
| Astellas Pharma | 2,060.61B |
| Daiichi Sankyo Company | 2,052.15B |
| Otsuka Holdings | 2,468.89B |
| Chugai Pharmaceutical | 1,257.94B |
| JCR Pharmaceuticals | 37.55B |
| Perseus Proteomics | 140.41M |
Kyowa Kirin News
- 6 days ago - Kyowa Kirin stops development of skin condition treatment - Reuters
- 5 weeks ago - Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends - Benzinga
- 3 months ago - Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman - Business Wire
- 3 months ago - Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting - GlobeNewsWire
- 4 months ago - Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region - Business Wire
- 4 months ago - Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases - GlobeNewsWire
- 4 months ago - Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan - GlobeNewsWire
- 7 months ago - Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers - GlobeNewsWire